Ceftazidime
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Ceftazidime | 1-2g IV QHD | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 547 | 60-85 | 1.2 | 13-25 | 5-24 | 0.18-0.31 | 60-155 | 41-81 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00438
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Leroy A, Leguy F, Borsa F, Spencer G, Fillastre J. Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects. Microbiology 1984; 25(5).
- Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
- Van Dalen R, Vree T, Baars A, Termond E. Dosage adjustment for ceftazidime in patients with impaired renal function. European journal of clinical pharmacology 1986; 30(5), 597-605.